The DOI matches its Crossref record; 71 of the 71 references it cites were found in a registry or an index.
Toward defining the preclinical stages of Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease
Open accessAbstract
The pathophysiological process of Alzheimer's disease (AD) is thought to begin many years before the diagnosis of AD dementia. This long “preclinical” phase of AD would provide a critical opportunity for therapeutic intervention; however, we need to further elucidate the link between the pathological cascade of AD and the emergence of clinical symptoms. The National Institute on Aging and the Alzheimer's Association convened an international workgroup to review the biomarker, epidemiological, and neuropsychological evidence, and to develop recommendations to determine the factors which best predict the risk of progression from “normal” cognition to mild cognitive impairment and AD dementia. We propose a conceptual framework and operational research criteria, based on the prevailing scientific evidence to date, to test and refine these models with longitudinal clinical research studies. These recommendations are solely intended for research purposes and do not have any clinical implications at this time. It is hoped that these recommendations will provide a common rubric to advance the study of preclinical AD, and ultimately, aid the field in moving toward earlier intervention at a stage of AD when some disease‐modifying therapies may be most efficacious.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The susceptibility of the conventional criteria for MCI to diagnostic error is likely to be amplified if used to characterize and stage preclinical AD—a pre-MCI categorization based on subtle cognitive decline [8].”
From Neuropsychological Criteria for Mild Cognitive Impairment Improves Diagnostic Precision, Biomarker Associations, and Progression Rates (2014) · cites this paper as [8]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In PET imaging, PIB and Florbetapir (AV45) amyloid tracers have shown greater cortical uptake in patients diagnosed with AD compared with control participants 11,57 .”
From OASIS-3: Longitudinal Neuroimaging, Clinical, and Cognitive Dataset for Normal Aging and Alzheimer Disease (2019) · cites this paper as [11]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Several anti-Aβ therapeutic strategies are being pursued to treat AD; however, it is likely that treatment will need to begin during the preclinical phase to prevent or limit plaque accumulation to be beneficial in reducing the risk of developing AD (51, 52).”
From Serotonin signaling is associated with lower amyloid-β levels and plaques in transgenic mice and humans (2011) · cites this paper as [52]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“New clinical diagnostic consensus criteria have now been finalized under the auspices of the NIA and Alzheimer's Association (52), with novel features including recognition of a preclinical stage of AD and the incorporation of imaging and laboratory-based cerebrospinal fluid biomarkers.”
From Accuracy of the Clinical Diagnosis of Alzheimer Disease at National Institute on Aging Alzheimer Disease Centers, 2005–2010 (2012) · cites this paper as [52]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Alzheimer’s disease (AD) begins several decades before the clinical onset of dementia with progressive amyloid accumulation preceding significant tau pathology and neurodegeneration.10,11”
From Machine learning reveals prominent spontaneous behavioral changes and treatment efficacy in humanized and transgenic Alzheimer's disease models (2024) · cites this paper as [11]
Experimental — accuracy not yet measured
The cited source says what the claim attributes to it.
In the citing paper
“Because there is evidence that the pathophysiology of AD likely begins many years before the emergence of clinical symptoms or a syndrome such as MCI or dementia”
From The Need to Separate Chronic Traumatic Encephalopathy Neuropathology from Clinical Features (2017) · cites this paper as [102]
The cited source says what the claim attributes to it.
In the citing paper
“Nevertheless, after decades of research, both the etiology and the pathophysiologic sequence of AD remain uncertain [102]”
From The Need to Separate Chronic Traumatic Encephalopathy Neuropathology from Clinical Features (2017) · cites this paper as [102]
The cited source says what the claim attributes to it.
In the citing paper
“This unifying research framework is a natural descendant of the 2011 NIA-AA preclinical AD recommendations that were based on the concept that AD, identified by biomarkers, can exist in the absence of symptoms [4].”
From NIA‐AA Research Framework: Toward a biological definition of Alzheimer's disease (2018) · cites this paper as [4]
The cited source says what the claim attributes to it.
In the citing paper
“Clinico-pathologic correlations for individuals without cognitive impairment should indicate that it is possible for AD neuropathologic change to predate onset of symptoms by years [54].”
From National Institute on Aging–Alzheimer’s Association guidelines for the neuropathologic assessment of Alzheimer’s disease: a practical approach (2012) · cites this paper as [54]
The cited source says what the claim attributes to it.
In the citing paper
“recognition that AD neuropathologic changes may occur in the apparent absence of cognitive impairment”
From National Institute on Aging–Alzheimer’s Association guidelines for the neuropathologic assessment of Alzheimer’s disease: a practical approach (2012) · cites this paper as [54]
The cited source says what the claim attributes to it.
In the citing paper
“This later point is important as the pathophysiological changes in the brain of people with AD require several years to occur.16”
From Cumulative Use of Strong Anticholinergics and Incident Dementia: A Prospective Cohort Study (2015) · cites this paper as [16]
The cited source says what the claim attributes to it.
In the citing paper
“The timing of therapeutic treatment in AD seems to be crucial as studies have shown that treating the disease too late has little efficacy (Sperling et al., 2011; Yiannopoulou et al., 2019).”
From Inhibiting USP16 rescues stem cell aging and memory in an Alzheimer’s model (2022) · cites this paper as Sperling et al., 2011
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“But their high cost and insufficient accessibility are being major limitations [12].”
From Integrated analysis of ultra-deep proteomes in cortex, cerebrospinal fluid and serum reveals a mitochondrial signature in Alzheimer’s disease (2020) · cites this paper as [12]
Experimental — accuracy not yet measuredIn the citing paper
“individuals remain cognitively normal for many years despite accumulating aggregates of Aβ plaques and tau neurofibrillary tangles (Sperling et al., 2011).”
From A Multi-network Approach Identifies Protein-Specific Co-expression in Asymptomatic and Symptomatic Alzheimer’s Disease (2017) · cites this paper as Sperling et al., 2011
In the citing paper
“The neuropathological changes of Alzheimer’s disease (AD) begin two decades or more before signs of cognitive impairment (Sperling et al., 2011).”
From A Multi-network Approach Identifies Protein-Specific Co-expression in Asymptomatic and Symptomatic Alzheimer’s Disease (2017) · cites this paper as Sperling et al., 2011
In the citing paper
“Additionally, we used the old criteria for the preclinical AD definition, while the recent research criteria also require tau positivity [8].”
From Duration of preclinical, prodromal, and dementia stages of Alzheimer's disease in relation to age, sex, and APOE genotype (2019) · cites this paper as [8]
In the citing paper
“Plaque formation rates also vary over time [217]. After a period of rapid accumulation, plaque deposition gradually slows and by the time symptoms manifest plaque deposition is essentially done [20, 205, 218].”
From The Alzheimer’s disease mitochondrial cascade hypothesis: progress and perspectives (2014) · cites this paper as [20]
In the citing paper
“The amyloid cascade hypothesis [14, 15], in conjunction with the newly designated preclinical AD category [20], necessarily infers cognitive changes that arise before plaques appear are etiologically unrelated to cognitive changes that arise after plaques appear.”
From The Alzheimer’s disease mitochondrial cascade hypothesis: progress and perspectives (2014) · cites this paper as [20]
In the citing paper
“In addition to using Aβ phenomena to distinguish AD from “normal” brain aging, the new criteria make one critical mechanistic assumption. Aβ is identified as an “upstream” AD biomarker [77]. Other biomarkers, including increased CSF tau, CSF phospho-tau, and decreased glucose utilization (as demonstrated by fluorodeoxyglucose PET; FDG PET), are identified as “downstream” biomarkers.”
From Brain aging, Alzheimer's disease, and mitochondria (2011) · cites this paper as [77]
In the citing paper
“According to the new AD diagnostic criteria cognitive decline and an absence of alternative dementia-associated pathology are no longer required features. At least for research purposes, to qualify for a diagnosis of AD altered brain or CSF Aβ is now the sole requirement [77].”
From Brain aging, Alzheimer's disease, and mitochondria (2011) · cites this paper as [77]
In the citing paper
“This is reflected by the recent adoption of AD diagnostic criteria that classify cognitively normal individuals with brain plaques or low cerebrospinal fluid Aβ levels as having “preclinical AD” [77].”
From Brain aging, Alzheimer's disease, and mitochondria (2011) · cites this paper as [77]
In the citing paper
“Studies of non-demented elderly cohorts overall report approximately 20–40% are PIB-positive [67, 68, 71–78].”
From Brain aging, Alzheimer's disease, and mitochondria (2011) · cites this paper as [77]
In the citing paper
“According to the new criteria, the primary dividing line between AD and brain aging is the presence or absence of brain or CSF Aβ changes.”
From Brain aging, Alzheimer's disease, and mitochondria (2011) · cites this paper as [77]
In the citing paper
“This asymptomatic phase of AD (AsymAD) is currently considered a preclinical stage of the disease [27, 28].”
From Deep proteomic network analysis of Alzheimer’s disease brain reveals alterations in RNA binding proteins and RNA splicing associated with disease (2018) · cites this paper as [28]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
McKhann, G. M., Knopman, D. S., Chertkow, H., Hyman, B. T., Jack, C. R., Kawas, C. H., Klunk, W. E., Koroshetz, W. J., Manly, J. J., Mayeux, R., et al. (2011) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.03.005 · Cited by 18,657
Self-citationNeuropathological stageing of Alzheimer-related changes.
Braak, H., & Braak, E. (1991) · Acta Neuropathologica · doi:10.1007/bf00308809 · Cited by 16,123 · cited 1×
“ries [68]) and the clinical syndrome of AD dementia (estimated prevalence from three epidemiological studies [69–71]).”
BackgroundAlbert, M. S., DeKosky, S. T., Dickson, D., Dubois, B., Feldman, H. H., Fox, N. C., Gamst, A., Holtzman, D. M., Jagust, W. J., Petersen, R. C., et al. (2011) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.03.008 · Cited by 10,152 · cited 1×
“This long “preclinical” phase of AD would provide a critical opportunity for therapeutic intervention; however, we need to further elucidate the link between the pathological cascade of AD and the emergence of clinical symptoms.”
BackgroundSelf-citationHypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade
Jack, C. R., Knopman, D. S., Jagust, W. J., Shaw, L. M., Aisen, P. S., Weiner, M. W., Petersen, R. C., & Trojanowski, J. Q. (2010) · The Lancet Neurology · doi:10.1016/s1474-4422(09)70299-6 · Cited by 4,806
Self-citationAlzheimer's Disease Is a Synaptic Failure
Selkoe, D. J. (2002) · Science · doi:10.1126/science.1074069 · Cited by 4,420
Shankar, G. M., Li, S., Mehta, T. H., Garcia-Munoz, A., Shepardson, N. E., Smith, I., Brett, F. M., Farrell, M. A., Rowan, M. J., Lemere, C. A., et al. (2008) · Nature Medicine · doi:10.1038/nm1782 · Cited by 3,685
Stern, Y. (2009) · Neuropsychologia · doi:10.1016/j.neuropsychologia.2009.03.004 · Cited by 2,943
Self-citationDecreased Clearance of CNS β-Amyloid in Alzheimer’s Disease
Mawuenyega, K. G., Sigurdson, W., Ovod, V., Munsell, L., Kasten, T., Morris, J. C., Yarasheski, K. E., & Bateman, R. J. (2010) · Science · doi:10.1126/science.1197623 · Cited by 2,078
Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects
Shaw, L. M., Vanderstichele, H., Knapik‐Czajka, M., Clark, C. M., Aisen, P. S., Petersen, R. C., Blennow, K., Soares, H., Simon, A., Lewczuk, P., et al. (2009) · Annals of Neurology · doi:10.1002/ana.21610 · Cited by 2,065
Self-citationJack, C. R., Albert, M. S., Knopman, D. S., McKhann, G. M., Sperling, R. A., Carrillo, M. C., Thies, B., & Phelps, C. H. (2011) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.03.004 · Cited by 2,042
Self-citation
Research works printed but not linked: 1
- JABecker DRentz JSCarmasin THedden IHamdi RLBuckner et al.Amyloid deposition and brain volume across the continuum of aging and AD.Ann Neurol2011(in press)
Cited by
Sorted by citations
Items 501–600 of 1,158
Brain injury biomarkers are not dependent on β‐amyloid in normal elderly
Knopman, D. S., Jack, C. R., Wiste, H. J., Weigand, S. D., Vemuri, P., Lowe, V. J., Kantarci, K., Gunter, J. L., Senjem, M. L., Mielke, M. M., et al. (2013) · Annals of Neurology · doi:10.1002/ana.23816 · Cited by 183
Self-citationInformatics and Computational Methods in Natural Product Drug Discovery: A Review and Perspectives
Romano, J. D., & Tatonetti, N. P. (2019) · Frontiers in Genetics · doi:10.3389/fgene.2019.00368 · Cited by 183
Guo, M., Peng, J., Huang, X., Xiao, L., Huang, F., & Zuo, Z. (2021) · Journal of Alzheimer s Disease · doi:10.3233/jad-201040 · Cited by 183
Vascular contributions to Alzheimer's disease
Eisenmenger, L. B., Peret, A., Famakin, B. M., Spahic, A., Roberts, G. S., Bockholt, J. H., Johnson, K. M., & Paulsen, J. S. (2022) · Translational research · doi:10.1016/j.trsl.2022.12.003 · Cited by 183
Yang, L., Yan, Y., Wang, Y., Hu, X., Lu, J., Chan, P., Yan, T., & Han, Y. (2018) · Frontiers in Neuroscience · doi:10.3389/fnins.2018.00975 · Cited by 182
McKeever, P. M., Schneider, R., Taghdiri, F., Weichert, A., Multani, N., Brown, R. A., Boxer, A. L., Karydas, A., Miller, B., Robertson, J., et al. (2018) · Molecular Neurobiology · doi:10.1007/s12035-018-1032-x · Cited by 166
Development of Positron Emission Tomography β-Amyloid Plaque Imaging Agents
Mathis, C. A., Mason, N. S., Lopresti, B. J., & Klunk, W. E. (2012) · Seminars in Nuclear Medicine · doi:10.1053/j.semnuclmed.2012.07.001 · Cited by 181
Early-onset Alzheimer's Disease: Nonamnestic Subtypes and Type 2 AD
Mendez, M. F. (2012) · Archives of Medical Research · doi:10.1016/j.arcmed.2012.11.009 · Cited by 181
Cognitive reserve and lifestyle: moving towards preclinical Alzheimer’s disease
Arenaza‐Urquijo, E. M., Wirth, M., & Chételat, G. (2015) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2015.00134 · Cited by 180
Morris, J. C. (2012) · Archives of Neurology · doi:10.1001/archneurol.2011.3152 · Cited by 180
Perrotin, A., La Joie, R., de La Sayette, V., Barré, L., Mézenge, F., Mutlu, J., Guilloteau, D., Egret, S., Eustache, F., & Chételat, G. (2017) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2016.08.011 · Cited by 179
Impaired default network functional connectivity in autosomal dominant Alzheimer disease
Chhatwal, J. P., Schultz, A. P., Johnson, K., Benzinger, T. L. S., Jack, C., Ances, B. M., Sullivan, C. A., Salloway, S. P., Ringman, J. M., Koeppe, R. A., et al. (2013) · Neurology · doi:10.1212/wnl.0b013e3182a1aafe · Cited by 179
Self-citationDiagnosis of Parkinson's Disease Based on Disease-Specific Autoantibody Profiles in Human Sera
Han, M. C., Nagele, E. P., DeMarshall, C. A., Acharya, N. K., & Nagele, R. G. (2012) · PLoS ONE · doi:10.1371/journal.pone.0032383 · Cited by 179
Boespflug, E. L., & Iliff, J. J. (2017) · Biological Psychiatry · doi:10.1016/j.biopsych.2017.11.031 · Cited by 179
Enhanced neural activation with blueberry supplementation in mild cognitive impairment
Boespflug, E. L., Eliassen, J. C., Dudley, J. A., Shidler, M. D., Kalt, W., Summer, S. S., Stein, A. L., Stover, A. N., & Krikorian, R. (2017) · Nutritional Neuroscience · doi:10.1080/1028415x.2017.1287833 · Cited by 178
AV-1451 PET imaging of tau pathology in preclinical Alzheimer disease: Defining a summary measure
Mishra, S., Gordon, B. A., Su, Y., Christensen, J. J., Friedrichsen, K. A., Jackson, K., Hornbeck, R. C., Balota, D. A., Cairns, N. J., Morris, J. C., et al. (2017) · NeuroImage · doi:10.1016/j.neuroimage.2017.07.050 · Cited by 178
Fleisher, A. S., Chen, K., Quiroz, Y. T., Jakimovich, L. J., Gutierrez Gomez, M., Langois, C. M., Langbaum, J. B. S., Roontiva, A., Thiyyagura, P., Lee, W., et al. (2015) · JAMA Neurology · doi:10.1001/jamaneurol.2014.3314 · Cited by 177
Self-citationQuantitative EEG power and synchronization correlate with Alzheimer's disease CSF biomarkers
Smailovic, U., Koenig, T., Kåreholt, I., Andersson, T., Kramberger, M. G., Winblad, B., & Jelic, V. (2018) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2017.11.005 · Cited by 177
Gallaway, P. J., Miyake, H., Buchowski, M. S., Shimada, M., YOSHITAKE, Y., Kim, A., & Hongu, N. K. (2017) · Brain Sciences · doi:10.3390/brainsci7020022 · Cited by 177
Brookmeyer, R., & Abdalla, N. (2018) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2018.03.005 · Cited by 176
Accelerated cortical atrophy in cognitively normal elderly with high β-amyloid deposition
Chételat, G., Villemagne, V. L., Villain, N., Jones, G. R., Ellis, K. A., Ames, D. J., Martins, R. N., Masters, C. L., & Rowe, C. C. (2012) · Neurology · doi:10.1212/wnl.0b013e318246d67a · Cited by 176
Self-citationAmyloid and tau imaging biomarkers explain cognitive decline from late middle-age
Betthauser, T. J., Koscik, R. L., Jonaitis, E. M., Allison, S. L., Cody, K. A., Erickson, C. M., Rowley, H. A., Stone, C. K., Mueller, K. D., Clark, L. R., et al. (2019) · Brain · doi:10.1093/brain/awz378 · Cited by 176
Role of mitochondrial homeostasis and dynamics in Alzheimer's disease
Selfridge, J. E., E, L., Lu, J., & Swerdlow, R. H. (2013) · Neurobiology of Disease · doi:10.1016/j.nbd.2011.12.057 · Cited by 175
Tau PET Imaging in Alzheimer’s Disease
Okamura, N., Harada, R., Furumoto, S., Arai, H., Yanai, K., & Kudo, Y. (2014) · Current Neurology and Neuroscience Reports · doi:10.1007/s11910-014-0500-6 · Cited by 175
Ledig, C., Schuh, A., Guerrero, R., Heckemann, R. A., & Rueckert, D. (2018) · Scientific Reports · doi:10.1038/s41598-018-29295-9 · Cited by 175
Ferrer, I. (2012) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2012.03.005 · Cited by 174
Association of brain pathology with the progression of frailty in older adults
Buchman, A. S., Yu, L., Wilson, R. S., Schneider, J. A., & Bennett, D. A. (2013) · Neurology · doi:10.1212/wnl.0b013e318294b462 · Cited by 174
Self-citationZhang, X., Mormino, E. C., Sun, N., Sperling, R. A., Sabuncu, M. R., Yeo, B. T. T., Initiative, T. A. D. N., Weiner, M. W., Aisen, P., Weiner, M. W., et al. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1611073113 · Cited by 174
Self-citationDai, Z., & He, Y. (2014) · Neuroscience Bulletin · doi:10.1007/s12264-013-1421-0 · Cited by 173
Buckley, R. F., Hanseeuw, B., Schultz, A. P., Vannini, P., Aghjayan, S. L., Properzi, M. J., Jackson, J. D., Mormino, E. C., Rentz, D. M., Sperling, R. A., et al. (2017) · JAMA Neurology · doi:10.1001/jamaneurol.2017.2216 · Cited by 173
Self-citationStructural progression of Alzheimer’s disease over decades: the MRI staging scheme
Planche, V., Manjón, J. V., Mansencal, B., Lanuza, E., Tourdias, T., Catheline, G., & Coupé, P. (2022) · Brain Communications · doi:10.1093/braincomms/fcac109 · Cited by 173
Irwin, D. J., Abrams, J. Y., Schonberger, L. B., Leschek, E., Mills, J. L., Lee, V. M. ‐., & Trojanowski, J. Q. (2013) · JAMA Neurology · doi:10.1001/jamaneurol.2013.1933 · Cited by 172
Multiple Brain Markers are Linked to Age-Related Variation in Cognition
Hedden, T., Schultz, A. P., Rieckmann, A., Mormino, E. C., Johnson, K. A., Sperling, R. A., & Buckner, R. L. (2014) · Cerebral Cortex · doi:10.1093/cercor/bhu238 · Cited by 172
Self-citationHearing Loss and Cognition: What We Know and Where We Need to Go
Powell, D. S., Oh, E. S., Reed, N. S., Lin, F. R., & Deal, J. A. (2022) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2021.769405 · Cited by 172
Wirth, M., Villeneuve, S., Haase, C. M., Madison, C. M., Oh, H., Landau, S. M., Rabinovici, G. D., & Jagust, W. J. (2013) · JAMA Neurology · doi:10.1001/jamaneurol.2013.4013 · Cited by 171
It's complicated: The relationship between sleep and Alzheimer's disease in humans
Lucey, B. P. (2020) · Neurobiology of Disease · doi:10.1016/j.nbd.2020.105031 · Cited by 172
Deng, Z., Wang, J., Xiao, Y., Li, F., Niu, L., Liu, X., Meng, L., & Zheng, H. (2021) · Theranostics · doi:10.7150/thno.52436 · Cited by 171
Hamzé, R., Delangre, E., Tolu, S., Moreau, M., Janel, N., Bailbé, D., & Movassat, J. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232315287 · Cited by 171
Rabinovici, G. D. (2019) · Continuum · doi:10.1212/con.0000000000000700 · Cited by 170
Subjective cognitive concerns, amyloid-β, and neurodegeneration in clinically normal elderly
Amariglio, R. E., Mormino, E. C., Pietras, A., Marshall, G. A., Vannini, P., Johnson, K. A., Sperling, R. A., & Rentz, D. M. (2015) · Neurology · doi:10.1212/wnl.0000000000001712 · Cited by 170
Self-citationUpadhaya, A. R., Kosterin, I., Kumar, S., Arnim, C. A. F. V., Yamaguchi, H., Fändrich, M., Walter, J., & Thal, D. R. (2014) · Brain · doi:10.1093/brain/awt362 · Cited by 170
Which Memory System is Impaired First in Alzheimer's Disease?
Didic, M., Barbeau, E. J., Félician, O., Tramoni, E., Guedj, É., Poncet, M., & Ceccaldi, M. P. (2011) · Journal of Alzheimer s Disease · doi:10.3233/jad-2011-110557 · Cited by 172
The sleep–wake Cycle and Alzheimer’s Disease: What do We know?
Lim, M. M., Gerstner, J. R., & Holtzman, D. M. (2014) · Neurodegenerative Disease Management · doi:10.2217/nmt.14.33 · Cited by 168
Marra, H., Myczkowski, M. L., Memória, C. M., Arnaut, D., Ribeiro, P. L., Mansur, C. G., Alberto, R. L., Bellini, B. B., da Silva, A. A. F., Tortella, G., et al. (2015) · Behavioural Neurology · doi:10.1155/2015/287843 · Cited by 166
Subjective cognitive decline: The first clinical manifestation of Alzheimer's disease?
Studart‐Neto, A., & Nitríni, R. (2016) · Dementia & Neuropsychologia · doi:10.1590/s1980-5764-2016dn1003002 · Cited by 167
Rocchi, A., Yamamoto, S., Ting, T., Fan, Y., Sadleir, K., Wang, Y., Zhang, W., Huang, S., Levine, B., Vassar, R., et al. (2017) · PLOS Genetics · doi:10.1371/journal.pgen.1006962 · Cited by 166
Dá Mesquita, S., Ferreira, A. C., Sousa, J. C., Correia-Neves, M., Sousa, N., & Marques, F. (2016) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2016.06.014 · Cited by 166
Episodic memory on the path to Alzheimer's disease
Gallagher, M., & Koh, M. T. (2011) · Current Opinion in Neurobiology · doi:10.1016/j.conb.2011.10.021 · Cited by 168
Risacher, S. L., WuDunn, D., Pepin, S. M., Magee, T., McDonald, B. C., Flashman, L. A., Wishart, H. A., Pixley, H. S., Rabin, L. A., Paré, N., et al. (2012) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2012.08.007 · Cited by 166
Boccardi, M., Bocchetta, M., Apostolova, L. G., Barnes, J., Bartzokis, G., Corbetta, G., DeCarli, C. S., deToledo‐Morrell, L., Firbank, M., Ganzola, R., et al. (2014) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2014.02.009 · Cited by 166
Self-citationWeissberger, G. H., Strong, J. V., Stefanidis, K. B., Summers, M. J., Bondi, M. W., & Stricker, N. H. (2017) · Neuropsychology Review · doi:10.1007/s11065-017-9360-6 · Cited by 169
Poor cognitive ageing: Vulnerabilities, mechanisms and the impact of nutritional interventions
Miquel, S., Champ, C., Day, J. E. L., Aarts, E., Bahr, B. A., Bakker, M. J., Bánáti, D., Calabrese, V., Cederholm, T., Cryan, J. F., et al. (2017) · Ageing Research Reviews · doi:10.1016/j.arr.2017.12.004 · Cited by 166
Gray matter atrophy pattern in elderly with subjective memory impairment
Peter, J., Scheef, L., Abdulkadir, A., Boecker, H., Heneka, M., Wagner, M., Koppara, A., Klöppel, S., Jessen, F., & Initiative, A. D. N. (2014) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2013.05.1764 · Cited by 165
Autopsy validation of 123 I-FP-CIT dopaminergic neuroimaging for the diagnosis of DLB
Thomas, A. J., Attems, J., Colloby, S. J., O'Brien, J. T., McKeith, I., Walker, R., Lee, L., Burn, D., Lett, D. J., & Walker, Z. (2017) · Neurology · doi:10.1212/wnl.0000000000003512 · Cited by 165
Guo, J., Wang, Z., Liu, R., Huang, Y., Zhang, N., & Zhang, R. (2020) · Brain and Behavior · doi:10.1002/brb3.1831 · Cited by 165
Machulda, M. M., Pankratz, V. S., Christianson, T. J. H., Ivnik, R. J., Mielke, M. M., Roberts, R. O., Knopman, D. S., Boeve, B. F., & Petersen, R. C. (2013) · The Clinical Neuropsychologist · doi:10.1080/13854046.2013.836567 · Cited by 165
Odor identification and Alzheimer disease biomarkers in clinically normal elderly
Growdon, M. E., Schultz, A. P., Dagley, A. S., Amariglio, R. E., Hedden, T., Rentz, D. M., Johnson, K. A., Sperling, R. A., Albers, M. W., & Marshall, G. A. (2015) · Neurology · doi:10.1212/wnl.0000000000001614 · Cited by 165
Self-citationJiang, Y., Zhou, X., Ip, F. C. F., Chan, P., Chen, Y., Lai, N. C. H., Cheung, K., Lo, R. M. N., Tong, E. P. S., Wong, B. W. Y., et al. (2021) · Alzheimer s & Dementia · doi:10.1002/alz.12369 · Cited by 166
Smith, R. G., Pishva, E., Shireby, G. L., Smith, A. R., Roubroeks, J. A. Y., Hannon, E. J., Wheildon, G., Mastroeni, D., Gasparoni, G., Riemenschneider, M. J., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-23243-4 · Cited by 176
Self-citationLazzaro, V. D., Bella, R., Benussi, A., Bologna, M., Borroni, B., Capone, F., Chen, K.-H. S., Chen, R. E., Chistyakov, A. V., Claßen, J., et al. (2021) · Clinical Neurophysiology · doi:10.1016/j.clinph.2021.05.035 · Cited by 163
Gene-environment interactions in Alzheimer's disease: A potential path to precision medicine
Eid, A., Mhatre, I., & Richardson, J. R. (2019) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2019.03.005 · Cited by 164
Fowler, C., Rainey-Smith, S. R., Bird, S., Bomke, J., Bourgeat, P., Brown, B. M., Burnham, S. C., Bush, A. I., Chadunow, C., Collins, S., et al. (2021) · Journal of Alzheimer's Disease Reports · doi:10.3233/adr-210005 · Cited by 164
Self-citationRutjes, A. W., Denton, D. A., Di Nisio, M., Chong, L.-Y., Abraham, R. P., Al-Assaf, A. S., Anderson, J. L., Malik, M. A., Vernooij, R. W., Martínez, G., et al. (2018) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd011906.pub2 · Cited by 164
A multiomics approach to heterogeneity in Alzheimer’s disease: focused review and roadmap
Badhwar, A., McFall, G. P., Sapkota, S., Black, S. E., Chertkow, H. M., Duchesne, S., Masellis, M., Li, L., Dixon, R. A., & Bellec, P. (2019) · Brain · doi:10.1093/brain/awz384 · Cited by 164
Amyloid precursor protein metabolism and inflammation markers in preclinical Alzheimer disease
Alcolea, D., Martínez-Lage, P., Sánchez-Juan, P., Olazarán, J., Antúnez, C., Izagirre, A., Ecay-Torres, M., Estanga, A., Clerigué, M., Guisasola, M. C., et al. (2015) · Neurology · doi:10.1212/wnl.0000000000001859 · Cited by 163
Indicators of amyloid burden in a population-based study of cognitively normal elderly
Mielke, M. M., Wiste, H. J., Weigand, S. D., Knopman, D. S., Lowe, V. J., Roberts, R. O., Geda, Y. E., Swenson-Dravis, D. M., Boeve, B. F., Senjem, M. L., et al. (2012) · Neurology · doi:10.1212/wnl.0b013e31826e2696 · Cited by 163
Self-citationSpatial navigation in young versus older adults
Gažová, I., Laczó, J., Rubínová, E., Mokrišová, I., Hynčicová, E., Andel, R., Vyhnálek, M., Sheardová, K., Coulson, E. J., & Hort, J. (2013) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2013.00094 · Cited by 163
Neuroimaging and Other Biomarkers for Alzheimer's Disease: The Changing Landscape of Early Detection
Risacher, S. L., & Saykin, A. J. (2013) · Annual Review of Clinical Psychology · doi:10.1146/annurev-clinpsy-050212-185535 · Cited by 163
Lanctôt, K. L., Hahn‐Pedersen, J. H., Eichinger, C. S., Freeman, C. S., Clark, A., Tarazona, L. R. S., & Cummings, J. L. (2023) · The Journal of Prevention of Alzheimer s Disease · doi:10.14283/jpad.2023.61 · Cited by 163
Genetic Susceptibility for Alzheimer Disease Neuritic Plaque Pathology
Shulman, J. M., Chen, K., Keenan, B. T., Chibnik, L. B., Fleisher, A., Thiyyagura, P., Roontiva, A., Aubin, C., Patsopoulos, N. A., Corneveaux, J. J., et al. (2013) · JAMA Neurology · doi:10.1001/jamaneurol.2013.2815 · Cited by 162
Self-citationEnsembles of Patch-Based Classifiers for Diagnosis of Alzheimer Diseases
Ahmed, S., Choi, K. Y., Lee, J. J., Kim, B. C., Kwon, G.-R., Lee, K. H., & Jung, H. Y. (2019) · IEEE Access · doi:10.1109/access.2019.2920011 · Cited by 162
A Pilot Study of Exenatide Actions in Alzheimer’s Disease
Mullins, R. J., Mustapić, M., Chia, C. W., Carlson, O. D., Gulyani, S., Tran, J., Li, Y., Mattson, M. P., Resnick, S. M., Egan, J. M., et al. (2019) · Current Alzheimer Research · doi:10.2174/1567205016666190913155950 · Cited by 162
Artificial Intelligence for Alzheimer’s Disease: Promise or Challenge?
Fabrizio, C., Termine, A., Caltagirone, C., & Sancesario, G. M. (2021) · Diagnostics · doi:10.3390/diagnostics11081473 · Cited by 163
Kester, M. I., Goos, J. D. C., Teunissen, C. E., Benedictus, M. R., Bouwman, F. H., Wattjes, M. P., Barkhof, F., Scheltens, P., & van der Flier, W. M. (2014) · JAMA Neurology · doi:10.1001/jamaneurol.2014.754 · Cited by 161
Prostaglandin signaling suppresses beneficial microglial function in Alzheimer’s disease models
Johansson, J. U., Woodling, N. S., Wang, Q., Panchal, M., Liang, X., Trueba-Saiz, A., Brown, H. D., Mhatre, S. D., Loui, T., & Andreasson, K. I. (2015) · Journal of Clinical Investigation · doi:10.1172/jci77487 · Cited by 161
Protas, H. D., Chen, K., Langbaum, J. B. S., Fleisher, A. S., Alexander, G. E., Lee, W., Bandy, D., de Leon, M. J., Mosconi, L., Buckley, S., et al. (2013) · JAMA Neurology · doi:10.1001/2013.jamaneurol.286 · Cited by 161
Self-citationCognition and beta-amyloid in preclinical Alzheimer's disease: Data from the AIBL study
Pike, K. E., Ellis, K. A., Villemagne, V. L., Good, N. M., Chételat, G., Ames, D. J., Szoeke, C. E. I., Laws, S. M., Verdile, G., Martins, R. N., et al. (2011) · Neuropsychologia · doi:10.1016/j.neuropsychologia.2011.04.012 · Cited by 161
Self-citationCosín‐Tomás, M., Antonell, A., Lladó, A., Alcolea, D. A., Fortea, J., Ezquerra, M., Lleó, A., Martı́, M. J., Pallàs, M., Sánchez‐Valle, R., et al. (2016) · Molecular Neurobiology · doi:10.1007/s12035-016-0088-8 · Cited by 161
ADCOMS: a composite clinical outcome for prodromal Alzheimer's disease trials
Wang, J., Logovinsky, V., Hendrix, S. B., Stanworth, S. H., Perdomo, C., Xu, L., Dhadda, S., Do, I., Rabe, M., Luthman, J., et al. (2016) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp-2015-312383 · Cited by 160
Progression of Alzheimer's disease as measured by Clinical Dementia Rating Sum of Boxes scores
Williams, M., Storandt, M., Roe, C. M., & Morris, J. C. (2012) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2012.01.005 · Cited by 160
Casanova, R., Varma, S., Simpson, B. N., Kim, M. G., An, Y., Saldana, S. J., Riveros, C., Moscato, P., Griswold, M. E., Sonntag, D., et al. (2016) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2015.12.008 · Cited by 161
Rabinovici, G. D., Carrillo, M. C., Forman, M. S., DeSanti, S., Miller, D. S., Kozauer, N., Petersen, R. C., RANDOLPH, C. C., Knopman, D. S., Smith, E. E., et al. (2016) · Alzheimer s & Dementia Translational Research & Clinical Interventions · doi:10.1016/j.trci.2016.09.002 · Cited by 160
Self-citationPower, M. C., Bennett, E. E., Turner, R., Dowling, N. M., Ciarleglio, A., Glymour, M. M., & Gianattasio, K. Z. (2020) · JAMA Neurology · doi:10.1001/jamaneurol.2020.4471 · Cited by 160
Thal, D. R., Beach, T. G., Zanette, M., Heurling, K., Chakrabarty, A., Ismail, A., Smith, A. P. L., & Buckley, C. (2015) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2015.05.018 · Cited by 159
Biomarkers in dementia: clinical utility and new directions
Ahmed, R. M., Paterson, R. W., Warren, J. D., Zetterberg, H., O'Brien, J. T., Fox, N. C., Halliday, G. M., & Schott, J. M. (2014) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp-2014-307662 · Cited by 159
Diagnosis and biomarkers of predementia in Alzheimer's disease
Forlenza, O. V., Diniz, B. S., & Gattaz, W. F. (2010) · BMC Medicine · doi:10.1186/1741-7015-8-89 · Cited by 160
An approach to studying the neural correlates of reserve
Stern, Y. (2016) · Brain Imaging and Behavior · doi:10.1007/s11682-016-9566-x · Cited by 159
Self-citationEarly-onset and delayed-onset poststroke dementia — revisiting the mechanisms
Mok, V., Lam, B. Y. K., Wong, A., Ko, H., Markus, H. S., & Wong, K. S. (2017) · Nature Reviews Neurology · doi:10.1038/nrneurol.2017.16 · Cited by 159
The Humanistic and Economic Burden of Alzheimer's Disease
Monfared, A. A. T., Byrnes, M. J., White, L. A., & Zhang, Q. (2022) · Neurology and Therapy · doi:10.1007/s40120-022-00335-x · Cited by 159
Predicting probable Alzheimer's disease using linguistic deficits and biomarkers
Orimaye, S. O., Wong, J. S.-M., Golden, K. J., Wong, C. P., & Soyiri, I. N. (2017) · BMC Bioinformatics · doi:10.1186/s12859-016-1456-0 · Cited by 158
Relationship between Exercise and Alzheimer’s Disease: A Narrative Literature Review
Meng, Q., Lin, M.-S., & Tzeng, I.-S. (2020) · Frontiers in Neuroscience · doi:10.3389/fnins.2020.00131 · Cited by 158
Zygouris, S., Giakoumis, D., Votis, K., Doumpoulakis, S., Ntovas, K., Segkouli, S., Karagiannidis, C., Tzovaras, D., & Tsolaki, M. (2015) · Journal of Alzheimer s Disease · doi:10.3233/jad-141260 · Cited by 158
Plasma microRNA biomarkers for detection of mild cognitive impairment
Sheinerman, K. S., Tsivinsky, V. G., Crawford, F., Mullan, M. J., Abdullah, L., & Umansky, S. R. (2012) · Aging · doi:10.18632/aging.100486 · Cited by 188
ApoE, ApoE Receptors, and the Synapse in Alzheimer's Disease
Lane-Donovan, C., & Herz, J. (2017) · Trends in Endocrinology & Metabolism · doi:10.1016/j.tem.2016.12.001 · Cited by 157
“Overt clinical symptoms typically do not appear until the underlying pathology is welldeveloped [8]; however, functional imaging studies suggest that changes in synaptic function occur several years before outward signs of the disease are apparent [9].”
BackgroundRobinson, J. L., Molina-Porcel, L., Corrada, M. M., Raible, K., Lee, E. B., Lee, V. M.-Y., Kawas, C. H., & Trojanowski, J. Q. (2014) · Brain · doi:10.1093/brain/awu190 · Cited by 157
Differential effects of cognitive reserve and brain reserve on cognition in Alzheimer disease
Groot, C., van Loenhoud, A. C., Barkhof, F., van Berckel, B. N. M., Koene, T., Teunissen, C. E., Scheltens, P., van der Flier, W. M., & Ossenkoppele, R. (2017) · Neurology · doi:10.1212/wnl.0000000000004802 · Cited by 157
Moynihan, R. N., Cooke, G., Doust, J. A., Bero, L. A., Hill, S. R., & Glasziou, P. (2013) · PLoS Medicine · doi:10.1371/journal.pmed.1001500 · Cited by 156
Amyloid-β diurnal pattern: possible role of sleep in Alzheimer's disease pathogenesis
Lucey, B. P., & Bateman, R. J. (2014) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2014.03.035 · Cited by 156
Albert, M., Soldan, A., Gottesman, R. F., McKhann, G. M., Sacktor, N. C., Farrington, L., Grega, M. A., Turner, R. S., Lu, Y., Li, S., et al. (2014) · Current Alzheimer Research · doi:10.2174/156720501108140910121920 · Cited by 158
Microglia-Specific Metabolic Changes in Neurodegeneration
Aldana, B. I. (2019) · Journal of Molecular Biology · doi:10.1016/j.jmb.2019.03.006 · Cited by 158
Metadata
- Authors
- Sperling, R. A., Aisen, P. S., Beckett, L. A., Bennett, D. A., Craft, S., Fagan, A. M., Iwatsubo, T., Jack, C. R., Kaye, J., Montine, T. J., Park, D. C., Reiman, E. M., Rowe, C. C., Siemers, E., Stern, Y., Yaffe, K., Carrillo, M. C., Thies, B., Morrison‐Bogorad, M., Wagster, M. V., & Phelps, C. H.
- Affiliations
- Brigham and Women's Hospital (US)
- University of California San Diego (US)
- University of California, Davis (US)
- Rush University Medical Center (US)
- University of Washington (US)
- Washington University in St. Louis (US)
- The University of Tokyo (JP)
- Mayo Clinic (US)
- Oregon Health & Science University (US)
- The University of Texas at Dallas (US)
- Banner Alzheimer’s Institute (US)
- The University of Melbourne (AU)
- Eli Lilly (United States) (US)
- Columbia University Irving Medical Center (US)
- San Francisco VA Medical Center (US)
- Alzheimer's Association Chicago IL USA
- Alzheimer's Association (US)
- National Institutes of Health (US)
- Corresponding author
- Sperling, Reisa A.
- ORCID
- Venue
- Alzheimer's & Dementia
- Publisher
- Wiley
- Published
- 2011-04-22
- Volume
- 7
- Issue
- 3
- Pages
- 280-292
- ISSN
- 1552-5260 (ISSN-L)
- 1552-5279
- PMC
- PMC3220946
- OpenAlex
- W2129497119
- Semantic Scholar
- 4718e61de2c928d77780b2a72fac704f18d8297b
- Cited by
- 7,155
- References
- 71
- Citations by year
- 2026: 375 · 2025: 467 · 2024: 485 · 2023: 445 · 2022: 534 · 2021: 575 · 2020: 550 · 2019: 533 · 2018: 513 · 2017: 471 · 2016: 468 · 2015: 461 · 2014: 417 · 2013: 418 · 2012: 302
- FWCI
- 277.90
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Alzheimer s & Dementia (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Columbia Academic Commons (Columbia University)
- Funders
- National Institute on Aging
- Pfizer
- Baxter International
- Johnson and Johnson
- Eli Lilly and Company
- Bayer
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Oncology › Cancer-related cognitive impairment studies
- Keywords
- Alzheimer's disease, preclinical Alzheimer's disease
- MeSH terms
- Alzheimer Disease, Cognition Disorders, Humans, United States, Biomarkers, Practice Guidelines as Topic, National Institute on Aging (U.S.)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
